Palabras clave
Transparencia
Competitividad
Innovación
Ética
DOI:
https://doi.org/10.17566/ciads.v10i3.775Cómo citar
Resumen
Objetivo: identificar los principales aspectos innovadores del Reglamento sobre ensayos clínicos de medicamentos de uso humano, en términos de oportunidades de investigación y desarrollo y reflexionar sobre los desafíos éticos de este nuevo marco legal. Metodología: estudio documental, descriptivo, comparativo del Reglamento en relación con la Directiva 2001/20/CE, y lectura de bibliografía publicada en PubMed, utilizando términos de investigación combinados o simples como clinical, trials, European, Regulation, Directive, opportunities, challenges y innovation. Resultados: los principales aspectos innovadores identificados fueron el Portal de presentación del expediente de ensayo clínico y evaluación conjunta entre los Estados miembros implicados en un ensayo clínico; disponibilidad pública de información, resultados de pruebas y un resumen de resultados para laicos; se creó la figura del co-promotor, categorías de pruebas según el riesgo; se han establecido nuevos procedimientos para obtener el consentimiento informado y requisitos para una mayor protección de las personas más vulnerables; y definió el marco regulatorio para la realización de ensayos clínicos en una situación de emergencia. Discusión: se prevén procedimientos para contrarrestar la pérdida de competitividad en Europa, promoviendo la innovación, algunas de las cuales no están exentas de cuestionamientos éticos. Conclusión: la simplificación, armonización y mayor transparencia en todo el proceso de envío y realización de ensayos clínicos tiene el potencial de promover la investigación, pero trae algunos aspectos inquietantes en términos de protección de los participantes en los ensayos clínicos.
Referencias
Parlamento Europeu e Conselho Europeu. Regulamento (UE) No 536/2014 do Parlamento Europeu e do Conselho de 16 de abril de 2014 relativo aos ensaios clínicos de medicamentos para uso humano e que revoga a Diretiva 2001/20/CE. J Of da União Eur. 2014; L 158:1–76.
Parlamento Europeu e Conselho Europeu. Diretiva 2001/20/CE do Parlamento Europeu e do Conselho de 4 de abril de 2001 relativa à aproximação das disposições legislativas, regulamentares e administrativas dos Estados-Membros respeitantes à aplicação de boas práticas clínicas na condução dos ensaios clínicos de medicamentos para uso humano. J Of da União Eur. 2001;121:34–44.
Gluud C, Kubiak C, Whitfield K, Byrne J, Huemer K, Thirstrup S, et al. Typical investigational medicinal products follow relatively uniform regulations in 10 European Clinical Research Infrastructures Network ( ECRIN ) countries. Trials. 2012;13:27.
Hernandez R, Cooney M, Dualé C, Gálvez M, Gaynor S, Kardos G, et al. Harmonisation of ethics committees’ practice in 10 European countries. J Med Ethics. 2009;35(11):696–700.
European Clinical Research Infrastructures Network - Transnational Working Groups (ECRIN-TWG). Deliverable 5. Meetings on the legislative and regulatory frameworks for clinical research in Europe. 2008.
Hartmann M. Impact assessment of the European Clinical Trials Directive: A longitudinal, prospective, observational study analyzing patterns and trends in clinical drug trial applications submitted since 2001 to regulatory agencies in six EU countries. Trials. 2012;13:53.
Boer AD, Schipper I. New EU regulation on clinical trials: the impact on ethics and safeguards for participants. Indian J Med Ethics. 2013;10(2):106–9
Califf RM. Clinical trials bureaucracy: Unintended consequences of well-intentioned policy. Clin Trials. 2006;3(6):496–502.
Petrini C. Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use: an overview. Ann Ist Super Sanità. 2014;50(4):317–321.
European Clinical Research Infrastructures Network - Transnational Working Groups (ECRIN-TWG). Deliverable 4. Clinical research in Europe: national differences in legislative and regulatory frameworks. 2008.
European Commission. Commission Staff Working Document. Impact assessment report on the revision of the “Clinical Trials Directive” 2001/20/EC accompanying the document Proposal for a Regulation of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. 2012.
Liddell K, Chamberlain D, Menon DK, Bion J, Kompanje EJO, Lemaire F, et al. The European Clinical Trials Directive revisited: The VISEAR recommendations. Resuscitation. 2006;69(1):9–14.
Hartmann M, Hartmann-Vareilles F. The Clinical Trials Directive: How Is It Affecting Europe’s Noncommercial Research. PLoS Clin Trials. 2006;1(2):e13.
Kenter MJH, Cohen AF. Re-engineering the European Union Clinical Trials Directive. Lancet. 2012;379:1765–7.
Abou-El-Enein M, Schneider CK. Deciphering the EU clinical trials regulation. 2016;34(3):231–3
Scavone C, Mauro G, Pietropaolo M, Alfano R, Berrino L, Rossi F, et al. The European Clinical Trials Regulation (No 536/2014): changes and challenges. Expert Rev Clin Pharmacol. 2019;12(11):1027–1032.
Gøtzsche PC. Deficiencies in proposed new EU regulation of clinical trials. BMJ. 2013;346(7890):9–12.
Frewer LJ, Coles D, Lans IA van der, Schroeder D, Champion K, Apperley JF. Impact of the European Clinical Trials Directive on prospective academic clinical trials associated with BMT. Bone Marrow Transplant. 2011;46:443–447.
Jeong S, Sohn M, Kim JH, Ko M, Seo HW, Song YK, et al. Current globalization of drug interventional clinical trials: Characteristics and associated factors, 2011-2013. Trials. 2017;18:288.
Walker E, Hankins MC, White SM. The effect of the European Clinical Trials Directive on published drug research in anaesthesia. 2009;64:984–989.
Giannuzzi V, Altavilla A. Clinical Trial Application in Europe: What Will Change with the New Regulation ? Sci Eng Ethics. 2016;22(2):451–66.
Cave E. EU clinical trials regulation 2014: Fetter or facilitator? Med Law Int. 2018;18(2–3):179–194.
Flear ML. The EU Clinical Trials Regulation: Key Priorities, Purposes and Aims and the Implications for Public Health. J Med Ethics. 2016;42(3):192–8.
European Medicines Agency (EMA). Clinical Trials Information System (CTIS) Training - Information update on progress. Vol. 31. 2021.
Barnes A, Patrick S. Lay Summaries of Clinical Study Results: An Overview. Pharmaceut Med. 2019;33(4):261–268.
Djurisic S, Rath A, Gaber S, Garattini S, Bertele V, Ngwabyt SN, et al. Barriers to the conduct of randomised clinical trials within all disease areas. Trials. 2017;18:360.
Toussaint B. EU Clinical Trials Regulation. Lancet. 2013;381(9879):1719–20.
Lemaire F, Matei M, Juvin P. New European Regulation for Clinical Trials of Medicinal Products. Am J Respir Crit Care Med 2015;191(1):16–18.
Madeira C, Santos F, Kubiak C, Demotes J. Transparency and accuracy in funding investigator-initiated clinical trials: a systematic search in clinical trials databases. BMJ Open. 2019;9:e023394.
European Commission. Council conclusions on personalised medicine for patients (2015/C 421/03). Of J Eur Union. 2015. C 421:1-5.
Gefenas E, Cekanauskaite A, Lekstutiene J, Lukaseviciene V. Application challenges of the new EU Clinical Trials Regulation. Eur J Clin Pharmacol. 2017;73(7):795–798.
Kim D, Hasford J. Redundant trials can be prevented if the EU clinical trial regulation is applied duly. BMC Med Ethics. 2020;21:107.
Lukaseviciene V, Hasford J, Lanzerath D, Gefenas E. Implementation of the EU clinical trial regulation transforms the ethics committee systems and endangers ethical standards. J Med Ethics. 2020;1–6.
Shaw D, Townend D. Division and discord in the clinical trials regulation. J Med Ethics. 2016;42(11):729–32.
Heringa J, Dute J. The proposed EU-regulation on clinical trials on medicinal products: An unethical proposal? Eur J Health Law. 2013;20(4):347–62.
Petrini C. What is the role of ethics committees after Regulation (EU) 536/2014? J Med Ethics. 2016;42(3):186–8.
World Medical Association. Declaration of Helsinki, Ethical Principles for Scientific Requirements and Research Protocols. Bull World Health Organ. 2013;79(4):373.
Unesco. Universal Declaration on Bioethics and Human Rights: UNESCO United Nations Educational, Scientific and Cultural Organization Universal Declaration on Bioethics and Human Rights: UNESCO; 2005.
International Ethical Guidelines for Health-related Research Involving Humans, Fourth Edition. Geneva. Council for International Organizations of Medical Sciences (CIOMS); 2016.
Council of Europe. Guide for Research Ethics Committee Members. Steering Committee on Bioethics. 2012.
European Commission. Regulation (EU) No 536/2014 Questions & Answers. Draft February 2021. 2021 [citado em 24.fev.2021]. Disponivel em: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/regulation5362014_qa_en.pdf
Dal-Ré R, Carné X. ¿Es tiempo de plantear ensayos clínicos de bajo nivel de intervención sin el consentimiento informado de los participantes? Is it time to discuss on low-intervention clinical trials without participants’ informed consent? Med Clin (Barc). 2018;150(9):345–7.
Westra AE. Ambiguous articles in new EU Regulation may lead to exploitation of vulnerable research subjects. J Med Ethics. 2016;42(3):189–91.
Gamble C, Woolfall K, Williamson P, Appleton R, Young B. New European Union regulation of clinical trials is conflicting on deferred consent in emergency situations. BMJ. 2013;346:f667.
Ostuzzi G, Gastaldon C, Barbui C. Poor implementation of the EU clinical trial regulation is a major threat for pragmatic trials in European countries. Epidemiol Psychiatr Sci. 2020;29(e126):1–3.
Tenti E, Simonetti G, Bochicchio MT, Martinelli G. Main changes in European Clinical Trials Regulation (No 536/2014). Contemp Clin Trials Commun. 2018;11(536):99–101.
Olimid AP, Olmid DA. Ethical review of patient safety and public health in EU clinical trials legislation: impact of COVID-19 pandemic. Rom J Morphol Embryol. 2020;61(1):277-281.
Glasa J, Glasová H. Ensuring an Appropriate Ethics Oversight under the New EU Clinical Trial Regulation: Challenges and Practicalities. Clin Ther. 2017;39(8):e97.
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Derechos de autor 2021 Maria Alexandra Ribeiro (Autor)